Stockholders’ Equity (Details) - USD ($)		1 Months Ended				6 Months Ended	12 Months Ended
	Feb. 09, 2021	Mar. 31, 2022	Jan. 31, 2022	Dec. 29, 2021	Jan. 18, 2021	Jun. 30, 2022	Dec. 31, 2021	Nov. 30, 2019	Apr. 30, 2013
Stockholders’ Equity (Details) [Line Items]
Shares authorized						505,000,000
Common stock, shares authorized						500,000,000	500,000,000
Preferred stock, shares authorized						5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)						$ 0.0001	$ 0.0001
Warrants term						5 years
Exercise price (in Dollars per share)						$ 0.3
Preferred stock conversion, description						The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.
Subsequent financing, percentage						50.00%
Liquidity damage, description						If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied.
Placement agent warrants, description						pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 2,850,664 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $0.35 per share, subject to adjustment.
Expired term				Dec. 26, 2026
Employment agreement, description			pursuant to an Employment Agreement (see Note 8), an aggregate of 800,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $0.20 per share and expires on January 31, 2032. The stock options vest as follows: (i) 300,000 stock options upon issuance; (ii) 250,000 vests on October 31, 2022 and; (iii) 250,000 vests on October 31, 2023.
Deferred compensation balance (in Dollars)						$ 35,782
Purchase agreement, description	the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 14,253,323 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $0.30 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 2,850,664 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $0.35 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.
Placement Agent Warrants [Member]
Stockholders’ Equity (Details) [Line Items]
Risk free interest rate						0.50%
Expected dividend yield						0.00%
Expected term						5 years
Expected volatility						169.00%
Aggregate grant date fair value of placement agent warrants (in Dollars)						$ 1,106,000
Warrant [Member]
Stockholders’ Equity (Details) [Line Items]
Warrants term					5 years
Exercise price (in Dollars per share)					$ 0.2
Risk free interest rate					0.46%
Expected term					5 years
Expected volatility					169.00%
Stock-based Compensation (in Dollars)							$ 83,728
Granted warrants to purchase shares					250,000
Grant date price per warrant (in Dollars per share)					$ 0.33
Warrant value (in Dollars)					$ 83,728
Stock price (in Dollars per share)					$ 0.35
Series A Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Designated shares of preferred stock									1,000,000
Share issued						0
Share outstanding						0
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized						2,000	2,000
Designated shares of preferred stock								2,000
Share issued
Share outstanding
Preferred stock, par value (in Dollars per share)						$ 0.0001	$ 0.0001
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Designated shares of preferred stock	4,280					4,280
Preferred stock, par value (in Dollars per share)						$ 0.0001
Preferred stock, stated value (in Dollars)						$ 1,000
Convertible preferred stock, description						A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.
Deemed dividend (in Dollars)	$ 1,403,997
Series C Conversion Price [Member]
Stockholders’ Equity (Details) [Line Items]
Conversion price per share (in Dollars per share)						$ 0.3
Series C Purchase Agreements [Member]
Stockholders’ Equity (Details) [Line Items]
Sale of aggregate shares	4,276
Warrant to purchase shares	14,253,323
Gross proceeds (in Dollars)	$ 4,276,000
Offering expenses (in Dollars)	$ 481,898
Series C Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized						4,280	4,280
Share issued						0	227
Share outstanding						0	227
Preferred stock, par value (in Dollars per share)						$ 0.0001	$ 0.0001
Converted preferred stock		227
Convertible common stock		758,334
Board Granted [Member]
Stockholders’ Equity (Details) [Line Items]
Exercise price (in Dollars per share)				$ 0.146
Risk free interest rate				0.75%
Expected term				2 years
Expected volatility				0.00%
Aggregate of incentive stock options				342,466
Stock option value (in Dollars)				$ 30,224
Expected volatility				115.00%
Fair value of unvested stock option				30,224
Fair value of the unvested stock options (in Dollars)						$ 15,122
Issuance of deferred compensation balance (in Dollars)						$ 15,122
Omnibus Equity incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares of common stock reserved and avail for issuance					8,500,000
Incentive Stock Option [Member]
Stockholders’ Equity (Details) [Line Items]
Risk free interest rate						1.18%
Expected dividend yield						0.00%
Expected term						2 years
Expected volatility						117.00%
Fair value of the unvested stock options (in Dollars)						$ 59,322
Stock option						800,000
Fair value of stock option (in Dollars)						$ 94,915
Stock-based Compensation (in Dollars)						$ 23,540